Cipla Limited Reports USFDA Inspection at InvaGen Manufacturing Facility
Cipla Limited has confirmed that the United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) inspection at an InvaGen Pharmaceuticals Inc. manufacturing facility. The facility is located in Central Islip, Long Island, New York, USA.The inspection took place over a five day period from July 13, 2026, to July 17, 2026 (EDT). InvaGen Pharmaceuticals Inc. is a wholly owned subsidiary of Cipla Limited.
Following the conclusion of the inspection, the company received one inspectional observation issued in Form 483. The company stated that it intends to work closely with the USFDA to address this observation comprehensively within the required timeframe.
CIPLA Stock Price Movement
Cipla Limited shares slipped by 0.70% on Friday to settle at ₹1,419.50. The stock saw a total traded volume of 607,055 shares as it retreated from the day's high.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.